Last reviewed · How we verify
AboBoNT-A
AboBoNT-A is a botulinum neurotoxin type A that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.
AboBoNT-A is a botulinum neurotoxin type A that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | AboBoNT-A |
|---|---|
| Also known as | Dysport® |
| Sponsor | Ipsen |
| Drug class | Botulinum neurotoxin type A |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Biologic |
| Therapeutic area | Neurology, Aesthetics, Pain Management |
| Phase | FDA-approved |
Mechanism of action
AboBoNT-A is a recombinant botulinum toxin serotype A produced using a cell-free protein synthesis system. It works by entering motor neurons and cleaving SNAP-25, a protein essential for acetylcholine vesicle release, thereby causing temporary paralysis of targeted muscles. This mechanism is used therapeutically to reduce muscle contractions in various conditions.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Spasticity
- Chronic migraine
- Glabellar lines (aesthetic indication)
Common side effects
- Injection site pain or bruising
- Headache
- Muscle weakness
- Ptosis (eyelid drooping)
- Dry mouth
Key clinical trials
- A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity. (PHASE4)
- The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia (PHASE4)
- Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort
- Observational Longitudinal Study on the Outbreak and Management of Stroke Related Spasticity
- A Study to Assess Treatment Outcomes of abobotulinumtoxinA and onabotulinumtoxinA Treatments in Real Life Practice in Toxin-naïve Adult Patients With Limb Spasticity.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AboBoNT-A CI brief — competitive landscape report
- AboBoNT-A updates RSS · CI watch RSS
- Ipsen portfolio CI